Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20993534 | 0.91 | KDM4E (0.38) | KDM4EALDH1A1 | |
| SCHEMBL10046329 | 0.88 | KDM4E (0.38) | KDM4EALDH1A1 | |
| SCHEMBL12980779 | 0.88 | KDM4E (0.38) | KDM4EALDH1A1 | |
| SCHEMBL21124844 | 0.87 | TSHR (0.37) | KDM4EALDH1A1CES2 | |
| SCHEMBL12981410 | 0.85 | TSHR (0.39) | KDM4EALDH1A1NPSR1HSD17B10CES2 | |
| SCHEMBL20993448 | 0.84 | GLP1R (0.37) | KDM4EALDH1A1POLB | |
| SCHEMBL20133152 | 0.83 | KDM4E (0.43) | KDM4EALDH1A1CES2POLB | |
| SCHEMBL4402902 | 0.83 | KDM4E (0.43) | KDM4EALDH1A1CES2POLB | |
| SCHEMBL20128726 | 0.83 | KDM4E (0.43) | KDM4EALDH1A1CES2POLB | |
| SCHEMBL27408407 | 0.83 | KDM4E (0.43) | KDM4EALDH1A1CES2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11197877-B2 | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists | GLYCOMIMETICS. INC. (US) | 2021-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11197877-B2 | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists | SELE, SELPLG, SELP | KDM4E 3860/4885ALDH1A1 371/4885NPSR1 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.